投资要点:对外授权收入带动业绩大幅增长,与阿斯利康订立全球战略合作协议。公司2025年上半年实现收入1.01亿美元((+327%);实现归母净利润0.73亿美元((+5125%)。其中,分子许可费收入由2083万美元增长至9371万美元((+350%)。2025年3月,公司在阿斯利康订立的合作协议中有资格获得预付款及潜在短期里程碑付款及额外项目的选择权行使费用1.75亿美元、最多44亿美元的额外...
Source Link投资要点:对外授权收入带动业绩大幅增长,与阿斯利康订立全球战略合作协议。公司2025年上半年实现收入1.01亿美元((+327%);实现归母净利润0.73亿美元((+5125%)。其中,分子许可费收入由2083万美元增长至9371万美元((+350%)。2025年3月,公司在阿斯利康订立的合作协议中有资格获得预付款及潜在短期里程碑付款及额外项目的选择权行使费用1.75亿美元、最多44亿美元的额外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.